Canagliflozin

Identification

Summary

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to manage hyperglycemia in type 2 diabetes mellitus (DM). Also used to reduce the risk of major cardiovascular events in patients with established cardiovascular disease and type 2 DM.

Brand Names

Invokamet, Invokana

Generic Name

Canagliflozin

DrugBank Accession Number

DB08907

Background

Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise ^Label.

It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus ⁸, ^Label.

Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes ⁸. Cardiovascular disease is the most common cause of death in these patients ⁴.

Type

Small Molecule

Groups

Approved

Structure

Similar Structures

Weight: Average: 444.516
Monoisotopic: 444.140672805
Chemical Formula: C₂₄H₂₅FO₅S

Synonyms

Canagliflozin
Canagliflozin anhydrous
Canagliflozina

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus ^Label.

Another indication for canagliflozin is the prevention of major cardiovascular events (myocardial infarction, stroke, or death due to a cardiovascular cause) in patients with type 2 diabetes, as well as hospitalization for heart failure in patients with type 2 diabetes^8,10.

In addition to the above, canagliflozin can be used to lower the risk of end-stage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus, diabetic nephropathy, and albuminuria.¹⁰

It is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis ^Label.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Used in combination to prevent	Cardiovascular mortality	Combination Product in combination with: Metformin (DB00331)	••••••••••••	•••••	•••••••• •••••••••••• •••• • •••••••• ••••••••• •••••••••••	••••••
Prevention of	Cardiovascular mortality		••••••••••••	•••••	•••••••••••• •••• • •••••••• ••••••••• •••••••• •••••••••••	••••••
Used in combination to prevent	End stage renal disease (esrd)	Combination Product in combination with: Metformin (DB00331)	••••••••••••	•••••	•••• • •••••••• ••••••••• •••••••• •••••••••••• •••••••••••	••••••
Prevention of	End stage renal disease (esrd)		••••••••••••	•••••	•••• • •••••••• ••••••••• •••••••• •••••••••••• •••••••••••	••••••
Used in combination to prevent	Hospitalizations	Combination Product in combination with: Metformin (DB00331)	••••••••••••	•••••	•••••••• •••••••••••• •••••••••••• •••• • •••••••• ••••••••	••••••

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

This drug increases urinary glucose excretion and decreases the renal threshold for glucose (RTG) in a dose-dependent manner ^Label. The renal threshold is defined as the lowest level of blood glucose associated with the appearance of detectable glucose in the urine ^2,7. The end result of canagliflozin administration is increased urinary excretion of glucose and less renal absorption of glucose, decreasing glucose concentration in the blood and improving glycemic control.

A note on type 2 diabetes and cardiovascular disease

The risk of cardiovascular events in diabetes type 2 is increased due to the damaging effects of diabetes on blood vessels and nerves in the cardiovascular system. In particular, there is a tendency for hyperglycemia to create pro-atherogenic (plaque forming) lesions in blood vessels, leading to various fatal and non-fatal events including stroke and myocardial infarction ^5,9. Long-term glycemic control has been proven to be effective in the prevention of cardiovascular events such as myocardial infarction and stroke in patients with type 2 diabetes ⁶.

Mechanism of action

The sodium-glucose co-transporter2 (SGLT2), is found in the proximal tubules of the kidney, and reabsorbs filtered glucose from the renal tubular lumen. Canagliflozin inhibits the SGLT2 co-transporter. This inhibition leads to lower reabsorption of filtered glucose into the body and decreases the renal threshold for glucose (RTG), leading to increased glucose excretion in the urine ^Label.

Target	Actions	Organism
ASodium/glucose cotransporter 2	inhibitor	Humans

Absorption

Bioavailability and steady-state

The absolute oral bioavailability of canagliflozin, on average, is approximately 65% ^Label. Steady-state concentrations are achieved after 4 to 5 days of daily dose administration between the range of 100mg to 300mg ^Label.

Effect of food on absorption

Co-administration of a high-fat meal with canagliflozin exerted no appreciable effect on the pharmacokinetic parameters of canagliflozin. This drug may be administered without regard to food. Despite this, because of the potential of canagliflozin to decrease postprandial plasma glucose excretion due to prolonged intestinal glucose absorption, it is advisable to take this drug before the first meal of the day ^Label.

Volume of distribution

This drug is extensively distributed throughout the body. On average, the volume of distribution of canagliflozin at steady state following a single intravenous dose in healthy patients was measured to be 83.5 L ^Label.

Protein binding

Canagliflozin is mainly bound to albumin. The plasma protein binding of this drug is 99% ^Label.

Metabolism

Canagliflozin is primarily metabolized by O-glucuronidation. It is mainly glucuronidated by UGT1A9 and UGT2B4 enzymes to two inactive O-glucuronide metabolites ^Label.

The oxidative metabolism of canagliflozin by hepatic cytochrome enzyme CYP3A4 is negligible (about 7%) in humans ^Label.

Hover over products below to view reaction partners

Canagliflozin
- Glucuronidated metabolites, canafliglozin
- Hydroxylated metabolite, canagliflozin

Route of elimination

After a single oral radiolabeled dose canagliflozin dose to healthy subjects, the following ratios of canagliflozin or metabolites were measured in the feces and urine ^Label:

Feces

41.5% as the unchanged radiolabeled drug

7.0% as a hydroxylated metabolite

3.2% as an O-glucuronide metabolite

Urine

About 33% of the ingested radiolabled dose was measured in the urine, generally in the form of O-glucuronide metabolites. Less than 1% of the dose was found excreted as unchanged drug in urine.

Half-life

In a clinical study, the terminal half-life of canagliflozin was 10.6 hours for the 100mg dose and 13.1 hours for the 300 mg dose ^Label.

Clearance

In healthy subjects, canagliflozin clearance was approximately 192 mL/min after intravenous (IV) administration ^Label.

The renal clearance of 100 mg and 300 mg doses of canagliflozin was measured to be in the range of 1.30 - 1.55 mL/min ^Label.

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Overdose information

If an overdose occurs, contact the Poison Control Center. Normal supportive measures should be taken, including the removal unabsorbed drug from the gastrointestinal tract, initiating clinical monitoring of the patient, and providing supportive treatment as deemed necessary. Canagliflozin has been removed in very small quantities after a 4-hour hemodialysis session. This drug is likely not dialyzable by peritoneal dialysis ^Label.

Pregnancy and lactation

Animal data has demonstrated that canagliflozin may cause adverse renal effects in a growing fetus. Data are insufficient at this time in determining a potential canagliflozin related risk for major birth defects or possible miscarriage in humans ^Label. There are known risks, however, of uncontrolled diabetes in pregnancy ^Label. Inform female patients taking canagliflozin of the potential risk, which is increased during the second and third trimesters. This drug is not recommended during nursing ^Label.

Mutagenesis and carcinogenicity

Canagliflozin was not found to be mutagenic in both metabolically activated and inactivated states in the Ames assay. Canagliflozin showed mutagenicity in laboratory mouse lymphoma assay, but only in the activated state. Canagliflozin was not found to be mutagenic in several in vivo assays performed on rats ^Label.

The carcinogenic risk of canagliflozin was assessed in 2-year studies completed in both CD1 mice and Sprague-Dawley rats. Canagliflozin was not shown to increase tumor incidence in mouse models given doses less than or equal to 14 times the exposure from a typical 300 mg dose in humans. Despite these negative findings in mice, the incidence of several tumors increased in mice, including Leydig cell tumors, renal tubular adenomas, and adrenal pheochromocytomas ^Label.

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Abacavir	Abacavir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Abaloparatide	The risk or severity of adverse effects can be increased when Abaloparatide is combined with Canagliflozin.
Abametapir	The serum concentration of Canagliflozin can be increased when it is combined with Abametapir.
Abemaciclib	The serum concentration of Abemaciclib can be increased when it is combined with Canagliflozin.
Abrocitinib	The serum concentration of Canagliflozin can be increased when it is combined with Abrocitinib.

Food Interactions

Avoid alcohol. Excess alcohol intake may promote ketoacidosis.
Drink plenty of fluids.
Take before a meal. It is recommended to take this drug before the first meal of the day.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Canagliflozin hydrate	0SAC974Z85	928672-86-0	VHOFTEAWFCUTOS-TUGBYPPCSA-N

Product Images

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Invokana	Tablet, film coated	100 mg/1	Oral	A-S Medication Solutions	2013-03-29	Not applicable
Invokana	Tablet, film coated	300 mg	Oral	Janssen Cilag International Nv	2020-12-16	Not applicable
Invokana	Tablet, film coated	300 mg/1	Oral	A-S Medication Solutions	2013-03-29	Not applicable
Invokana	Tablet, film coated	100 mg	Oral	Janssen Cilag International Nv	2020-12-16	Not applicable
Invokana	Tablet	100 mg	Oral	Janssen Pharmaceuticals	2014-06-03	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Invokamet	Canagliflozin hydrate (150 mg/1) + Metformin hydrochloride (1000 mg/1)	Tablet, film coated	Oral	Janssen Pharmaceuticals, Inc.	2014-08-08	Not applicable
Invokamet	Canagliflozin hydrate (50 mg/1) + Metformin hydrochloride (500 mg/1)	Tablet, film coated	Oral	Janssen Pharmaceuticals, Inc.	2014-08-08	Not applicable
Invokamet	Canagliflozin hydrate (150 mg/1) + Metformin hydrochloride (500 mg/1)	Tablet, film coated	Oral	Janssen Pharmaceuticals, Inc.	2014-08-08	Not applicable
Invokamet	Canagliflozin (50 mg) + Metformin hydrochloride (850 mg)	Tablet	Oral	Janssen Pharmaceuticals	2016-06-28	2022-09-06
Invokamet	Canagliflozin (50 mg) + Metformin hydrochloride (1000 mg)	Tablet	Oral	Janssen Pharmaceuticals	2016-06-28	Not applicable

Chemical Identifiers

UNII: 6S49DGR869
CAS number: 842133-18-0
InChI Key: XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
InChI: InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
IUPAC Name: (2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1

References

General References

Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [Article]
Osaki A, Okada S, Saito T, Yamada E, Ono K, Niijima Y, Hoshi H, Yamada M: Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy. J Diabetes Investig. 2016 Sep;7(5):751-4. doi: 10.1111/jdi.12473. Epub 2016 Feb 16. [Article]
Deeks ED, Scheen AJ: Canagliflozin: A Review in Type 2 Diabetes. Drugs. 2017 Sep;77(14):1577-1592. doi: 10.1007/s40265-017-0801-6. [Article]
Joseph JJ, Golden SH: Type 2 diabetes and cardiovascular disease: what next? Curr Opin Endocrinol Diabetes Obes. 2014 Apr;21(2):109-20. doi: 10.1097/MED.0000000000000044. [Article]
Gleissner CA, Galkina E, Nadler JL, Ley K: Mechanisms by which diabetes increases cardiovascular disease. Drug Discov Today Dis Mech. 2007;4(3):131-140. doi: 10.1016/j.ddmec.2007.12.005. [Article]
Mannucci E, Dicembrini I, Lauria A, Pozzilli P: Is glucose control important for prevention of cardiovascular disease in diabetes? Diabetes Care. 2013 Aug;36 Suppl 2:S259-63. doi: 10.2337/dcS13-2018. [Article]
Steven L. Cowart and Max E. Stachura (1990). Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. (3rd ed.). Butterworths.
U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease [Link]
Diabetes, Heart Disease, and Stroke: NIDDK [Link]
FDA Approved Drug Products: Invokana (canagliflozin) oral tablets [Link]
FDA Approved Products: INVOKAMET (canagliflozin and metformin hydrochloride tablets), for oral use [Link]
FDA Approved Drug Products: Invokana (canagliflozin) tablets for oral use (July 2023) [Link]
Invokana, Canadian monograph [File]

External Links

KEGG Drug: D09592
PubChem Compound: 24812758
PubChem Substance: 175427146
ChemSpider: 26333259
BindingDB: 50386885
RxNav: 1373458
ChEBI: 73274
ChEMBL: CHEMBL2048484
ZINC: ZINC000043207238
PDBe Ligand: L3R
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Canagliflozin

PDB Entries

8hdh

FDA label

Download (687 KB)

MSDS

Download (24.7 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Active Not Recruiting	Treatment	Coronavirus Disease 2019 (COVID‑19)	1
4	Active Not Recruiting	Treatment	Type 2 Diabetes Mellitus	2
4	Completed	Treatment	Albuminuria / Type 2 Diabetes Mellitus	1
4	Completed	Treatment	Diabetes Mellitus	1
4	Completed	Treatment	Hearth Failure With Reduced Ejection Fraction (HFrEF) / Type 2 Diabetes Mellitus	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Tablet	Oral
Tablet, film coated	Oral
Tablet, extended release	Oral
Tablet, film coated, extended release	Oral
Tablet	Oral	100 mg
Tablet	Oral	300 mg
Tablet	Oral	300.000 mg
Tablet, film coated	Oral	100 mg/1
Tablet, film coated	Oral	300 mg/1
Tablet, film coated	Oral
Tablet, film coated	Oral	100 mg
Tablet, film coated	Oral	300 mg
Tablet, coated	Oral
Tablet, film coated	Oral	150.00 mg
Tablet, film coated	Oral	50.00 mg
Tablet, coated	Oral	100 mg
Tablet, coated	Oral	300 mg

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US6723340	No	2004-04-20	2021-10-25
US8222219	No	2012-07-17	2024-07-30
US8513202	No	2013-08-20	2027-12-03
US7943582	No	2011-05-17	2029-02-26
US8785403	No	2014-07-22	2024-07-30
US7943788	No	2011-05-17	2027-07-14
US10617668	No	2020-04-14	2031-05-11
US11576894	No	2010-07-06	2030-07-06

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	68-72	https://www.trc-canada.com/product-detail/?CatNum=C175190
boiling point (°C)	‎642.9±55.0	http://www.chemspider.com/Chemical-Structure.26333259.html
water solubility	almost insoluble	https://www.ema.europa.eu/en/documents/assessment-report/invokana-epar-public-assessment-report_en.pdf
logP	3.44	https://www.tga.gov.au/file/824/download
pKa	13.34	https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103841/

Predicted Properties

Property	Value	Source
Water Solubility	0.0045 mg/mL	ALOGPS
logP	3.09	ALOGPS
logP	3.52	Chemaxon
logS	-5	ALOGPS
pKa (Strongest Acidic)	12.57	Chemaxon
pKa (Strongest Basic)	-3	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	5	Chemaxon
Hydrogen Donor Count	4	Chemaxon
Polar Surface Area	90.15 Å²	Chemaxon
Rotatable Bond Count	5	Chemaxon
Refractivity	116.14 m³·mol^-1	Chemaxon
Polarizability	46.64 Å³	Chemaxon
Number of Rings	4	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9541
Blood Brain Barrier	+	0.7708
Caco-2 permeable	-	0.6554
P-glycoprotein substrate	Substrate	0.6058
P-glycoprotein inhibitor I	Non-inhibitor	0.8414
P-glycoprotein inhibitor II	Non-inhibitor	0.9447
Renal organic cation transporter	Non-inhibitor	0.8544
CYP450 2C9 substrate	Non-substrate	0.6853
CYP450 2D6 substrate	Non-substrate	0.8293
CYP450 3A4 substrate	Non-substrate	0.5929
CYP450 1A2 substrate	Non-inhibitor	0.6579
CYP450 2C9 inhibitor	Non-inhibitor	0.6178
CYP450 2D6 inhibitor	Non-inhibitor	0.8683
CYP450 2C19 inhibitor	Non-inhibitor	0.5958
CYP450 3A4 inhibitor	Non-inhibitor	0.7086
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.7691
Ames test	Non AMES toxic	0.584
Carcinogenicity	Non-carcinogens	0.9103
Biodegradation	Not ready biodegradable	0.9936
Rat acute toxicity	2.5975 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9912
hERG inhibition (predictor II)	Non-inhibitor	0.7246

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0002-0110900000-6c638b8cc9b7c8253bc1
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-05fr-0010900000-780b01732bb78212c604
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0059-0293500000-971fac7697402f469e04
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0a4l-6329400000-05216d0f205e9b7873c0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-01pk-1195400000-ed127b8052948e8ac04c
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-0a4l-4349000000-4f678932f3ddaddb0cdb
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å²)	Source type	Source
[M-H]-	200.55614	predicted	DeepCCS 1.0 (2019)
[M+H]+	202.45152	predicted	DeepCCS 1.0 (2019)
[M+Na]+	208.35258	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	6.7	N/A	N/A	A30609

Details1. Sodium/glucose cotransporter 2

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Low-affinity glucose:sodium symporter activity
Specific Function: Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capac...
Gene Name: SLC5A2
Uniprot ID: P31639
Uniprot Name: Sodium/glucose cotransporter 2
Molecular Weight: 72895.995 Da

References

Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [Article]
FDA label, Invokana [File]
Invokana, Canadian monograph [File]

Enzymes

Details1. UDP-glucuronosyltransferase 1-9

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Retinoic acid binding
Specific Function: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name: UGT1A9
Uniprot ID: O60656
Uniprot Name: UDP-glucuronosyltransferase 1-9
Molecular Weight: 59940.495 Da

References

Sarnoski-Brocavich S, Hilas O: Canagliflozin (invokana), a novel oral agent for type-2 diabetes. P T. 2013 Nov;38(11):656-66. [Article]
Devineni D, Vaccaro N, Murphy J, Curtin C, Mamidi RN, Weiner S, Wang SS, Ariyawansa J, Stieltjes H, Wajs E, Di Prospero NA, Rothenberg P: Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28. doi: 10.5414/CP202158. [Article]
FDA label, Invokana [File]
Invokana, Canadian monograph [File]

Details2. UDP-glucuronosyltransferase 2B4

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Glucuronosyltransferase activity
Specific Function: UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as...
Gene Name: UGT2B4
Uniprot ID: P06133
Uniprot Name: UDP-glucuronosyltransferase 2B4
Molecular Weight: 60512.035 Da

References

Sarnoski-Brocavich S, Hilas O: Canagliflozin (invokana), a novel oral agent for type-2 diabetes. P T. 2013 Nov;38(11):656-66. [Article]
Devineni D, Vaccaro N, Murphy J, Curtin C, Mamidi RN, Weiner S, Wang SS, Ariyawansa J, Stieltjes H, Wajs E, Di Prospero NA, Rothenberg P: Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28. doi: 10.5414/CP202158. [Article]
FDA label, Invokana [File]
Invokana, Canadian monograph [File]

Details3. Cytochrome P450 3A4

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

Mosley JF 2nd, Smith L, Everton E, Fellner C: Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview. P T. 2015 Jul;40(7):451-62. [Article]
FDA label, Invokana [File]

Carriers

Details1. Alpha-1-acid glycoprotein 1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Not Available
Specific Function: Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name: ORM1
Uniprot ID: P02763
Uniprot Name: Alpha-1-acid glycoprotein 1
Molecular Weight: 23511.38 Da

References

Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [Article]

Transporters

Details1. P-glycoprotein 1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

References

Mamidi RNVS, Dallas S, Sensenhauser C, Lim HK, Scheers E, Verboven P, Cuyckens F, Leclercq L, Evans DC, Kelley MF, Johnson MD, Snoeys J: In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096. doi: 10.1111/bcp.13186. Epub 2016 Dec 20. [Article]
Devineni D, Vaccaro N, Murphy J, Curtin C, Mamidi RN, Weiner S, Wang SS, Ariyawansa J, Stieltjes H, Wajs E, Di Prospero NA, Rothenberg P: Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28. doi: 10.5414/CP202158. [Article]
FDA label, Invokana [File]
Invokana, Canadian monograph [File]

Details2. Canalicular multispecific organic anion transporter 1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Organic anion transmembrane transporter activity
Specific Function: Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name: ABCC2
Uniprot ID: Q92887
Uniprot Name: Canalicular multispecific organic anion transporter 1
Molecular Weight: 174205.64 Da

References

Invokana, Canadian monograph [File]

Details3. ATP-binding cassette sub-family G member 2

Kind: Protein
Organism: Humans
Pharmacological action: Unknown

General Function: Xenobiotic-transporting atpase activity
Specific Function: High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name: ABCG2
Uniprot ID: Q9UNQ0
Uniprot Name: ATP-binding cassette sub-family G member 2
Molecular Weight: 72313.47 Da

References

Invokana, Canadian monograph [File]

Drug created at June 17, 2013 06:21 / Updated at February 20, 2024 23:55

Canagliflozin

Identification

Structure for Canagliflozin (DB08907)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)

Targets

References

Enzymes

References

References

References

Carriers

References

Transporters

References

References

References